Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Natural killer (NK) cells participate in the regulation of the immune response. However, the immunomodulatory function of NK cells in
systemic lupus erythematosus
(
SLE
) is not well understood. The aim of this study was to evaluate the regulatory function of NK cells in
SLE
patients and to identify the NK cells involved in the pathogenesis of this complex disease. We analysed the expression of NK receptors and co-stimulatory molecules in peripheral NK cells (CD3
-
CD56
+
) from
SLE
patients, as well as the numbers of
human leucocyte antigen D
-related (HLA-DR)/CD11c
+
NK cells. In addition, NK cell regulatory function was assessed by the detection of NK cell-mediated dendritic cell (DC) lysis. We found that
SLE
patients showed increased numbers of immunoglobulin-like transcript 2 (ILT2)
+
, CD86
+
and CD134
+
NK cells. Furthermore, NK cells from
SLE
patients induced higher levels of DC lysis. We were able to identify a new subset of NK cells co-expressing CD11c and HLA-DR. These atypical NK cells were increased in
SLE
patients when compared with controls. We have identified an expanded new subset of NK cells in
SLE
patients. This is the first study, to our knowledge, which demonstrates that NK cells in
SLE
patients have an altered phenotype with a high expression of receptors characteristic of dendritic cells. Our results suggest that the impairment in the regulatory function of NK cells, together with the increased number of DC-like NK cells, could play an important role in the development of
SLE
and highlight the importance of NK cells as a future therapeutic target.
...
PMID:Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus. 2905 8